Patent application number | Description | Published |
20100112686 | SHORT HAIRPIN RNAS FOR INHIBITION OF GENE EXPRESSION - Methods, compositions, and kits that include small hairpin RNA (shRNA) useful for inhibition of gene expression, such as viral-mediated gene expression, are described. | 05-06-2010 |
20110269816 | Inhibition of Viral Gene Expression Using Small Interfering RNA - The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) that are useful for inhibition of viral-mediated gene expression. Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targetING the internal ribosome entry site (IRES) sequence of HCV are described. | 11-03-2011 |
20120165397 | CHEMICAL MODIFICATION OF SHORT SMALL HAIRPIN RNAS FOR INHIBITION OF GENE EXPRESSION - Aspects of the present invention include the production and use of chemically modified RNAi agents (e.g., shRNAs) in gene silencing applications. The chemically modified RNAi agents disclosed herein have reduced immunostimulatory activity, increased serum stability, or both, as compared to a corresponding RNAi agent not having the chemical modification. Compositions containing chemically modified RNAi agents according to aspects of the present invention (including pharmaceutical compositions) and kits containing the same are also provided. | 06-28-2012 |
20120220033 | INHIBITION OF VIRAL GENE EXPRESSION USING SMALL INTERFERING RNA - The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) that are useful for inhibition of viral-mediated gene expression. Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targetING the internal ribosome entry site (IRES) sequence of HCV are described. | 08-30-2012 |
20150152414 | CHEMICAL MODIFICATION OF SHORT SMALL HAIRPIN RNAS FOR INHIBITION OF GENE EXPRESSION - Aspects of the present invention include the production and use of chemically modified RNAi agents (e.g., shRNAs) in gene silencing applications. The chemically modified RNAi agents disclosed herein have reduced immunostimulatory activity, increased serum stability, or both, as compared to a corresponding RNAi agent not having the chemical modification. Compositions containing chemically modified RNAi agents according to aspects of the present invention (including pharmaceutical compositions) and kits containing the same are also provided. | 06-04-2015 |